Daniel Meuser sold Amgen Inc (NASDAQ: AMGN)
Daniel Meuser (R-PA), a U.S. Representative, has disclosed 1 trade in Amgen Inc (AMGN) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Daniel Meuser sold $1,001 - $15,000 of Amgen Inc (NASDAQ: AMGN) on February 11, 2025. Since that trade, AMGN is up +36.88% against the S&P 500 up +24.31%, an outperformance of +12.57%.
Data updated
Daniel Meuser's AMGN trades vs the price
AMGN is up +36.88% since Daniel Meuser sold on February 11, 2025, versus +24.31% for the S&P 500.
Performance since this trade
All Daniel Meuser AMGN trades
Daniel Meuser & AMGN trading FAQ
Is it legal for Daniel Meuser to trade Amgen Inc (AMGN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Amgen Inc (AMGN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Daniel Meuser sell AMGN?
Daniel Meuser disclosed a sale of $1,001 - $15,000 of Amgen Inc (AMGN) on February 11, 2025, according to public STOCK Act filings.
How has AMGN performed since Daniel Meuser's trade?
Since Daniel Meuser sold AMGN on February 11, 2025, the stock is up +36.88%, versus +24.31% for the S&P 500 over the same period, an outperformance of +12.57%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AMGN trades?
Quantellect tracks every disclosed congressional trade in Amgen Inc (AMGN) on the Amgen Inc congressional trading page, which aggregates filings across all members of Congress.
Daniel Meuser's AMGN tradesAll congressional filings for Amgen IncDaniel Meuser's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.